Member Info for RayPointer

Lets see if it breaks the resistance at about 8.5

Yes, I see what you mean.
There will also no doubt be common work in developing all the Tags in one ongoing project.
It certainly should be more efficient to tackle it as 1 project.
So it may just boil down to a race between the 3 collaborators.

No, I'm saying that because our 3 collaborators may be in different continents (we don't know where the first collaborator is located but 2nd and 3rd are in China and US respectively) separate deals may be possible for US, China (or Asia) and Europe.

An example is the recent IMM deal that gives their partner sole rights to the product in the US.

So all 3 could do deals on a geographical basis for the same Tag or Tags.
Who knows, but it may have already been discussed with our collaborators.

Morning Chester

Yes, this is an added benefit of Avidimab.
It can be applied to other existing mabs.
So, our 3 collaborators :
Are they just assessing Scancell's Tag mabs or are they additionally assessing Avidimab to enhance their own existing mabs?

Maybe they plan to assess the tag mabs first as specified in the RNSs but they may also want to do further work on their own mabs.
So, the deals if and when they come, may be on specific tag mabs first and may be geographically based. Then there may be further deals on specific existing mabs.
Who know just how deals will be structured but there is potential for many deals.

Oh and we do have 2 teams on this BB.
Team ramp and team damp.
We regularly have football matches without a football.
We prefer to kick each other and so the final score always ends up being 0-0.
We are being investigated by the FA, not because they are thinking of banning our form of football but because it is proving to be be more entertaining that the normal form of the game.

And we are definitely not homophobic on this BB.
We love homocitrullination which presents another set of very promising targets to be exploited by Modi2.
Then further down the line citrullination and homocitrullination plan to get married. Maybe a match made in heaven.

This was posted about yesterday, since the same research was reported by the BBC

https://www.bbc.co.uk/news/health-51182451

You might be interested in last night's discussion on this BB.
ATB

Trades 44, 4 reccs at 4 minutes to 1.
I would have recc'd your post but I didn't want to spoil the symmetry.

Look at the 3 year chart.
10p was a strong support level but when broken became strong resistance not yet broken.

Well
1) Do they mean phase I/II?
2) SCIB2 or Modi1?
3) SCIB2 and skin cancer - NO

So should the statement be
"A phase I/ II trial of Modi1 in head and neck/ovarian/TNBC cancer is due to get underway within a matter of weeks"
or
"A phase I/ II trial of SCIB2 in NSCLC is due to get underway within a matter of weeks"

"A phase II trial of SCIB2 in skin cancer is due to get underway within a matter of weeks."

I don't know what to say about that. How many errors?

C7
I think the interest has always been there. It's just not been visible until Scancell opened their doors to pre-clinical collaborations.

I'm not sure I agree.
Sure, Scancell could have an article about them on the BBC website and it would attract some interest.
But how long would that interest last and would the Beeb be likely to follow up on the article before the next big story breaks.
So you would probably end up with a temporary effect. Much like a lot of Scancell's news items. In fact, even with today's news item we do not know how long the effect will last.
IMO, what is of more importance is that scientists in other companies and countries are recognising the worth of Scancell's products and persuading their management that a closer look is required.
The result is 4 pre-clinical collaborations.
How many more would there have been if Scancell were looking for pre-clinical deals on their 2 main platforms.

So, as investors, you look for accumulated evidence that Scancell have indeed something worth shouting about.
For me, that accumulated evidence is in the 4 collaborations, the CAB, the GC team members, the SCIB1 peer reviews, Keith Flaherty's support for SCIB1, CRUK funding and running the SCIB2 trial, Lindy winning the Waldenström prize, Diggles following Peter James's advice.
All of the above are endorsements from scientists.
So, if the Daily Mail or the BBC published an article about Scancell tomorrow, that wouldn't make my list. It might make nice reading though.

The sustained price rises will come with trials starting (with patients), data and deals. We all hope this eventually starts to happen this year.

I'm pretty sure all the glycans mabs have Avidimab since the whole idea was to give them back their killing capability.
I'm not sure about 2811 (see poster)

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/2811-cicon19-paris-jc.pdf

However, this mab, is 1 of a kind at present. Not a glycans Mab.
I also wondered if any of our collaborators are also looking at Avidimab for their own mabs. If so, it does increase the possibilities.

Only joking. Perhaps someone has just returned from a visit to the bank manager.

I was just about to mention your buy, roses

Iclavert, no news on the SCIB1 trial, either on the IND re-submission or the possible enlargement of the UK trial.

Maybe we will hear more when the Interims are released (last year it was 31st Jan).

Lindy is conducting experiments on humanised penguins as we speak
With the help of Batman I suspect

It might freeze the SP

OR deals, if and when the come, could be on a geographical basis (ref the recent IMM deal).
We don't know where the first collaborator is located but it may well be Europe.
If it is, then we have collaborators located each in one of the 3 main continents.

I can't wait for the Antarctica collaboration to be announced.